Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment (AEIPDT)
Drug: Alprazolam + Aerobic exercise
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial|
- Participants´Endpoint Change From Baseline in Hamilton Anxiety Rating Scale [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Participants´Endpoint Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Participants´Endpoint Change From Baseline in Clinical Global Impression Improvement Scale (CGI-I) [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||July 2005|
|Study Completion Date:||October 2008|
|Primary Completion Date:||July 2008 (Final data collection date for primary outcome measure)|
|Active Comparator: Alprazolam||
The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.
Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.
|Active Comparator: Alprazolam + Aerobic exercise||
Drug: Alprazolam + Aerobic exercise
The patients assigned to exercise have to pass an ergometric test to determine the functional capacity expressed in Metabolic Equivalents of Task (METs), and their maximum heart rates to standardize the future exercise indication.
Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.
At the same time they have to follow a protocolized aerobic exercise plan for this study 3 times a week for 12 weeks.
The type of selected exercise consists of a rapid walk (both in not inclined treadmill or natural courses) for 30 minutes divided in stages.
After each stage the patient has to control his own heart frequency that has to be maintained between 50 and 75% of their maximum not to turn to an anaerobic condition, according to the American Cardiological Association.
We have observed in our clinical practice that patients who practiced aerobic physical exercise had faster remissions and better improvement in their treatments that those who did not. There are also some scientific studies that included physical exercise in the treatment for panic disorder and compared them to other single pharmacological treatments.
So our objective will be to compare the efficacy of a pharmacological monotherapy (alprazolam), that is one of the options for the pharmacological treatment of panic disorder, with other treatment such as the combination of aerobic physical exercise and alprazolam, and to determine if this combination results in a better therapeutic response.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00803400
|Psychiatry Academic Unit at J.A.Fernandez Hospital, University of Buenos Aires Medicine School Department of Mental Health|
|Buenos Aires, Capital Federal, Argentina, 1425|
|Principal Investigator:||Marcelo G Rudelir, MD||Psychiatry Academic Unit at J.A.Fernandez Hospital, University of Buenos Aires Medicine School Department of Psychiatry|